Mortality and morbidity in common variable immunodeficiency

被引:51
作者
Aghamohammadi, Asghar [1 ]
Pouladi, Nima
Parvaneh, Nima
Yeganeh, Mehdi
Movahedi, Masoud
Gharagolou, Mohamad
Pourpak, Zahra
Rezaei, Nima
Salavati, Ali
Abdollahzade, Sina
Moin, Mostafa
机构
[1] Childrens Med Ctr, Div Clin Immunol, Dept Pediat, Tehran, Iran
[2] Childrens Med Ctr, Immunol Asthma & Allergy Res Inst, Tehran, Iran
[3] Univ Tehran Med Sci, Students Sci Res Ctr, Tehran, Iran
关键词
D O I
10.1093/tropej/fml077
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Common variable immunodeficiency (CVID) is a heterogeneous group of disorders, characterized by hypogammaglobulinemia, defective specific-antibody production resulting in recurrent bacterial infections. Delay in diagnosis and inadequate treatment result in increased irreversible complications and mortality. To determine persistent morbidities, mortality rate and survival in Iranian patients with CVID, hospital records of 72 (39 males and 33 females) diagnosed CVID patients were reviewed. Probabilities of survival after diagnosis of CVID were estimated from Kaplan-Meier life tables. Studied patients were enrolled over a 20-year period (1984-2005). The most commonly observed complication was bronchiectasis (24 cases), followed by splenomegaly, intestinal villous atrophy (11 cases), and failure to thrive (10 cases). Post-diagnosis survival was estimated as 65% for the first 6.5 years, which remains the same until 14 years after diagnosis when the survival curve drops to nearly 45%. The mortality rate among patients who had no regular visits and did not receive periodical IVIG was more remarkable when compared with those who had been followed up timely (p-value = 0.001).The most common cause of death was respiratory failure. Based on our observation, it can be highlighted that all patients with CVID, even under regular immunoglobulin replacement, need close monitoring for early detection of complications and introduction of appropriate management.
引用
收藏
页码:32 / 38
页数:7
相关论文
共 42 条
[1]  
Abonia JP, 2002, ALLERGY ASTHMA PROC, V23, P53
[2]   Lymphoma of mucosa-associated lymphoid tissue in common variable immunodeficiency [J].
Aghamohammadi, A ;
Parvaneh, N ;
Tirgari, F ;
Mahjoob, F ;
Movahedi, M ;
Gharagozlou, M ;
Mansouri, M ;
Kouhi, A ;
Rezaei, N ;
Webster, D .
LEUKEMIA & LYMPHOMA, 2006, 47 (02) :343-346
[3]   Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency [J].
Aghamohammadi, A ;
Farhoudi, A ;
Moin, M ;
Rezaei, N ;
Kouhi, A ;
Pourpak, Z ;
Yaseri, N ;
Movahedi, M ;
Gharagozlou, M ;
Zandieh, F ;
Yazadni, F ;
Arshi, S ;
MohammadZadeh, I ;
Ghazi, BM ;
Mahmoudi, M ;
Tahaei, S ;
Isaeian, A .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (07) :825-832
[4]   Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia [J].
Aghamohammadi, A ;
Moin, M ;
Farhoudi, A ;
Rezaei, N ;
Pourpak, Z ;
Movahedi, M ;
Gharagozlou, M ;
Nabavi, M ;
Shahrokhi, A .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2004, 40 (02) :113-118
[5]   Autoimmunity in human primary immunodeficiency diseases [J].
Arkwright, PD ;
Abinun, M ;
Cant, AJ .
BLOOD, 2002, 99 (08) :2694-2702
[6]   Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency [J].
Bates, CA ;
Ellison, MC ;
Lynch, DA ;
Cool, CD ;
Brown, KK ;
Routes, JM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (02) :415-421
[7]   PRIMARY ANTIBODY DEFICIENCY AND DIAGNOSTIC DELAY [J].
BLORE, J ;
HAENEY, MR .
BRITISH MEDICAL JOURNAL, 1989, 298 (6672) :516-517
[8]   Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency [J].
Busse, PJ ;
Razvi, S ;
Cunningham-Rundles, C .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (06) :1001-1004
[9]   The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency [J].
Carsetti, R ;
Rosado, MM ;
Donnanno, S ;
Guazzi, V ;
Soresina, A ;
Meini, M ;
Plebani, A ;
Aiuti, F ;
Quinti, I .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2005, 115 (02) :412-417
[10]   The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy [J].
Chapel, HM ;
Spickett, GP ;
Ericson, D ;
Engl, W ;
Eibl, MM ;
Bjorkander, J .
JOURNAL OF CLINICAL IMMUNOLOGY, 2000, 20 (02) :94-100